Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Denis M. Collins(Dublin City University), Birgit Bossenmaier(Roche Pharma AG (Germany))
Cited by 54
Related Papers
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
|Clinical Cancer Research|2020|75
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
|British Journal of Cancer|2023|12